Pharsight

Drugs that contain Balsalazide Disodium

1. Colazal patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7452872 VALEANT PHARMS INTL Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
Aug, 2026

(2 years from now)

US7625884 VALEANT PHARMS INTL Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
Aug, 2026

(2 years from now)

US7452872

(Pediatric)

VALEANT PHARMS INTL Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
Feb, 2027

(2 years from now)

US7625884

(Pediatric)

VALEANT PHARMS INTL Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
Feb, 2027

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Pediatric Exclusivity(PED) Jun 20, 2014
Orphan Drug Exclusivity(ODE) Dec 20, 2013

Market Authorisation Date: 18 July, 2000

Treatment: Treatment of ulcerative colitis

Dosage: CAPSULE;ORAL

How can I launch a generic of COLAZAL before it's drug patent expiration?
More Information on Dosage

COLAZAL family patents

Family Patents

2. Giazo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6197341 VALEANT PHARMS INTL Formulations of balsalazide and its derivatives
Mar, 2018

(6 years ago)

US9192616 VALEANT PHARMS INTL Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
Aug, 2026

(2 years from now)

US7452872 VALEANT PHARMS INTL Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
Aug, 2026

(2 years from now)

US7625884 VALEANT PHARMS INTL Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
Aug, 2026

(2 years from now)

US8497256 VALEANT PHARMS INTL Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives for the treatment of males
Jun, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) Feb 03, 2015

Market Authorisation Date: 03 February, 2012

Treatment: Treatment of mildly to moderately active ulcerative colitis in male patients

Dosage: TABLET;ORAL

How can I launch a generic of GIAZO before it's drug patent expiration?
More Information on Dosage

GIAZO family patents

Family Patents